Form 4: Rapport Therapeutics COO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock for approximately $280,000 through a pre-arranged trading plan.
Summary
- Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc. (RAPP), reported the sale of common stock.
- The transactions occurred on March 30, 2026.
- A total of 10,000 shares of common stock were disposed of in two separate transactions.
- The first transaction involved 7,161 shares sold at a weighted average price of $28.0401 per share, with prices ranging from $27.42 to $28.41.
- The second transaction involved 2,839 shares sold at a weighted average price of $28.553 per share, with prices ranging from $28.42 to $28.72.
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- Following these transactions, Cheryl Gault beneficially owns 159,914 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of an insider stock sale executed under a pre-arranged 10b5-1 trading plan, which typically does not carry significant positive or negative implications for the company's operational performance or future prospects.
Industry Context
StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are common and typically pre-scheduled, often for diversification or liquidity purposes, rather than being a direct reaction to immediate company performance or outlook. Such transactions are generally viewed as routine disclosures within the biotechnology or pharmaceutical industry.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in insider ownership, but given it's under a 10b5-1 plan, it's unlikely to signal a change in management confidence or have a material impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/10/2025 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 03/30/2026 | Date of reported stock transactions (sales). |
| 03/31/2026 | Date the Form 4 filing was signed. |
Keywords
Rapport Therapeutics, RAPP, Insider Trading, Form 4, Stock Sale, Cheryl Gault, Chief Operating Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.